tiprankstipranks
Trending News
More News >
Exelixis (EXEL)
:EXEL
US Market
Advertisement

Exelixis (EXEL) Stock Forecast & Price Target

Compare
3,048 Followers
See the Price Targets and Ratings of:

EXEL Analyst Ratings

Moderate Buy
20Ratings
Moderate Buy
11 Buy
9 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Exelixis
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EXEL Stock 12 Month Forecast

Average Price Target

$44.72
▲(19.38% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $44.72 with a high forecast of $60.00 and a low forecast of $36.00. The average price target represents a 19.38% change from the last price of $37.46.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","31":"$31","41":"$41","51":"$51","61":"$61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,31,41,51,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.62,44.879999999999995,46.14,47.4,48.66,49.92,51.18,52.44,53.7,54.96,56.22,57.480000000000004,58.74,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.62,43.70461538461538,43.78923076923077,43.87384615384615,43.958461538461535,44.043076923076924,44.12769230769231,44.21230769230769,44.29692307692307,44.38153846153846,44.466153846153844,44.55076923076923,44.635384615384616,{"y":44.72,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.62,43.03384615384615,42.44769230769231,41.86153846153846,41.27538461538462,40.68923076923077,40.10307692307692,39.51692307692308,38.93076923076923,38.34461538461538,37.75846153846154,37.17230769230769,36.58615384615385,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.25,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.03,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.12,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.62,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$60.00Average Price Target$44.72Lowest Price Target$36.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on EXEL
TipRanks AITipRanks
Not Ranked
TipRanks
$41
Buy
9.45%
Upside
Reiterated
07/31/25
Exelixis demonstrates strong financial performance and a positive outlook from recent earnings. However, technical indicators suggest near-term challenges. Valuation remains moderate, supporting a stable investment thesis.
UBS
$43$38
Hold
1.44%
Upside
Reiterated
07/30/25
Exelixis price target lowered to $38 from $43 at UBSExelixis price target lowered to $38 from $43 at UBS
Guggenheim Analyst forecast on EXEL
Michael SchmidtGuggenheim
Guggenheim
$45
Buy
20.13%
Upside
Reiterated
07/29/25
Exelixis (EXEL) Gets a Buy from Guggenheim
TD Cowen Analyst forecast on EXEL
Yaron WerberTD Cowen
TD Cowen
$44
Buy
17.46%
Upside
Reiterated
07/29/25
TD Cowen Sticks to Their Buy Rating for Exelixis (EXEL)
Wells Fargo Analyst forecast on EXEL
Derek ArchilaWells Fargo
Wells Fargo
$36
Hold
-3.90%
Downside
Reiterated
07/29/25
Exelixis Stock Performance: Hold Rating Amid Earnings Miss and Strategic Concerns
William Blair Analyst forecast on EXEL
Andy HsiehWilliam Blair
William Blair
Buy
Reiterated
07/29/25
Exelixis's Long-Term Growth Potential: Buy Rating Backed by Strong Fundamentals and Promising Drug Pipeline
RBC Capital Analyst forecast on EXEL
Leonid TimashevRBC Capital
RBC Capital
$50$45
Hold
20.13%
Upside
Reiterated
07/29/25
Exelixis (EXEL) Gets a Hold from RBC Capital
Stifel Nicolaus Analyst forecast on EXEL
Stephen WilleyStifel Nicolaus
Stifel Nicolaus
$38$41
Hold
9.45%
Upside
Reiterated
07/29/25
Exelixis (EXEL) Receives a Hold from Stifel Nicolaus
Morgan Stanley Analyst forecast on EXEL
Sean LaamanMorgan Stanley
Morgan Stanley
$48$46
Buy
22.80%
Upside
Reiterated
07/29/25
Exelixis's Cabometyx Gains Strong Market Share in Neuroendocrine Tumors, Exceeding Expectations
Bank of America Securities Analyst forecast on EXEL
Jason GerberryBank of America Securities
Bank of America Securities
Hold
Reiterated
07/29/25
Bank of America Securities Reaffirms Their Hold Rating on Exelixis (EXEL)
Oppenheimer Analyst forecast on EXEL
Jay OlsonOppenheimer
Oppenheimer
$36
Hold
-3.90%
Downside
Reiterated
07/29/25
Exelixis (EXEL) Receives a Hold from Oppenheimer
Leerink Partners Analyst forecast on EXEL
Andrew BerensLeerink Partners
Leerink Partners
$39$38
Hold
1.44%
Upside
Reiterated
07/29/25
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), aTyr Pharma (NASDAQ: ATYR) and HCA Healthcare (NYSE: HCA)
Citizens JMP Analyst forecast on EXEL
Silvan TuerkcanCitizens JMP
Citizens JMP
$50
Buy
33.48%
Upside
Reiterated
07/29/25
Citizens JMP Keeps Their Buy Rating on Exelixis (EXEL)
Barclays Analyst forecast on EXEL
Peter LawsonBarclays
Barclays
$40
Hold
6.78%
Upside
Reiterated
07/29/25
Barclays Sticks to Their Hold Rating for Exelixis (EXEL)
Truist Financial Analyst forecast on EXEL
Asthika GoonewardeneTruist Financial
Truist Financial
$56$49
Buy
30.81%
Upside
Reiterated
07/29/25
Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on EXEL
TipRanks AITipRanks
Not Ranked
TipRanks
$41
Buy
9.45%
Upside
Reiterated
07/31/25
Exelixis demonstrates strong financial performance and a positive outlook from recent earnings. However, technical indicators suggest near-term challenges. Valuation remains moderate, supporting a stable investment thesis.
UBS
$43$38
Hold
1.44%
Upside
Reiterated
07/30/25
Exelixis price target lowered to $38 from $43 at UBSExelixis price target lowered to $38 from $43 at UBS
Guggenheim Analyst forecast on EXEL
Michael SchmidtGuggenheim
Guggenheim
$45
Buy
20.13%
Upside
Reiterated
07/29/25
Exelixis (EXEL) Gets a Buy from Guggenheim
TD Cowen Analyst forecast on EXEL
Yaron WerberTD Cowen
TD Cowen
$44
Buy
17.46%
Upside
Reiterated
07/29/25
TD Cowen Sticks to Their Buy Rating for Exelixis (EXEL)
Wells Fargo Analyst forecast on EXEL
Derek ArchilaWells Fargo
Wells Fargo
$36
Hold
-3.90%
Downside
Reiterated
07/29/25
Exelixis Stock Performance: Hold Rating Amid Earnings Miss and Strategic Concerns
William Blair Analyst forecast on EXEL
Andy HsiehWilliam Blair
William Blair
Buy
Reiterated
07/29/25
Exelixis's Long-Term Growth Potential: Buy Rating Backed by Strong Fundamentals and Promising Drug Pipeline
RBC Capital Analyst forecast on EXEL
Leonid TimashevRBC Capital
RBC Capital
$50$45
Hold
20.13%
Upside
Reiterated
07/29/25
Exelixis (EXEL) Gets a Hold from RBC Capital
Stifel Nicolaus Analyst forecast on EXEL
Stephen WilleyStifel Nicolaus
Stifel Nicolaus
$38$41
Hold
9.45%
Upside
Reiterated
07/29/25
Exelixis (EXEL) Receives a Hold from Stifel Nicolaus
Morgan Stanley Analyst forecast on EXEL
Sean LaamanMorgan Stanley
Morgan Stanley
$48$46
Buy
22.80%
Upside
Reiterated
07/29/25
Exelixis's Cabometyx Gains Strong Market Share in Neuroendocrine Tumors, Exceeding Expectations
Bank of America Securities Analyst forecast on EXEL
Jason GerberryBank of America Securities
Bank of America Securities
Hold
Reiterated
07/29/25
Bank of America Securities Reaffirms Their Hold Rating on Exelixis (EXEL)
Oppenheimer Analyst forecast on EXEL
Jay OlsonOppenheimer
Oppenheimer
$36
Hold
-3.90%
Downside
Reiterated
07/29/25
Exelixis (EXEL) Receives a Hold from Oppenheimer
Leerink Partners Analyst forecast on EXEL
Andrew BerensLeerink Partners
Leerink Partners
$39$38
Hold
1.44%
Upside
Reiterated
07/29/25
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), aTyr Pharma (NASDAQ: ATYR) and HCA Healthcare (NYSE: HCA)
Citizens JMP Analyst forecast on EXEL
Silvan TuerkcanCitizens JMP
Citizens JMP
$50
Buy
33.48%
Upside
Reiterated
07/29/25
Citizens JMP Keeps Their Buy Rating on Exelixis (EXEL)
Barclays Analyst forecast on EXEL
Peter LawsonBarclays
Barclays
$40
Hold
6.78%
Upside
Reiterated
07/29/25
Barclays Sticks to Their Hold Rating for Exelixis (EXEL)
Truist Financial Analyst forecast on EXEL
Asthika GoonewardeneTruist Financial
Truist Financial
$56$49
Buy
30.81%
Upside
Reiterated
07/29/25
Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exelixis

1 Month
xxx
Success Rate
17/28 ratings generated profit
61%
Average Return
+7.69%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.71% of your transactions generating a profit, with an average return of +7.69% per trade.
3 Months
xxx
Success Rate
23/28 ratings generated profit
82%
Average Return
+24.06%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 82.14% of your transactions generating a profit, with an average return of +24.06% per trade.
1 Year
Yaron WerberTD Cowen
Success Rate
19/24 ratings generated profit
79%
Average Return
+21.59%
reiterated a buy rating 10 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 79.17% of your transactions generating a profit, with an average return of +21.59% per trade.
2 Years
xxx
Success Rate
21/28 ratings generated profit
75%
Average Return
+76.65%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +76.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EXEL Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
0
0
0
0
Buy
40
28
29
37
41
Hold
22
12
11
17
29
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
62
40
40
54
70
In the current month, EXEL has received 41 Buy Ratings, 29 Hold Ratings, and 0 Sell Ratings. EXEL average Analyst price target in the past 3 months is 44.72.
Each month's total comprises the sum of three months' worth of ratings.

EXEL Financial Forecast

EXEL Earnings Forecast

Next quarter’s earnings estimate for EXEL is $0.68 with a range of $0.53 to $0.72. The previous quarter’s EPS was $0.75. EXEL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year EXEL has Outperformed its overall industry.
Next quarter’s earnings estimate for EXEL is $0.68 with a range of $0.53 to $0.72. The previous quarter’s EPS was $0.75. EXEL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year EXEL has Outperformed its overall industry.

EXEL Sales Forecast

Next quarter’s sales forecast for EXEL is $590.43M with a range of $571.52M to $633.00M. The previous quarter’s sales results were $568.26M. EXEL beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year EXEL has Outperformed its overall industry.
Next quarter’s sales forecast for EXEL is $590.43M with a range of $571.52M to $633.00M. The previous quarter’s sales results were $568.26M. EXEL beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year EXEL has Outperformed its overall industry.

EXEL Stock Forecast FAQ

What is EXEL’s average 12-month price target, according to analysts?
Based on analyst ratings, Exelixis’s 12-month average price target is 44.72.
    What is EXEL’s upside potential, based on the analysts’ average price target?
    Exelixis has 19.38% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is EXEL a Buy, Sell or Hold?
          Exelixis has a consensus rating of Moderate Buy which is based on 11 buy ratings, 9 hold ratings and 0 sell ratings.
            What is Exelixis’s price target?
            The average price target for Exelixis is 44.72. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $60.00 ,the lowest forecast is $36.00. The average price target represents 19.38% Increase from the current price of $37.46.
              What do analysts say about Exelixis?
              Exelixis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of EXEL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis